<DOC>
	<DOC>NCT03076515</DOC>
	<brief_summary>This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.</brief_summary>
	<brief_title>Migraine Treatment With Nerivio Migra Neurostimulation Device</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1. Patient is 1875 years old. 2. Patient meeting the ICHD3 diagnostic criteria for migraine with and without aura. 3. Patients reporting 28 migraine attacks per month. 4. Patient must be able and willing to comply with the protocol. 5. Patient must be able and willing to provide written informed consent. 6. Male or nonpregnant / nonlactating female (NOTE: Females of child bearing potential must have a negative pregnancy test) and must be willing to use adequate contraceptive means during the study 1. Has other significant pain problem that in the opinion of the investigator may confound the study assessments 2. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagus nerve neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator). 3. Known uncontrolled epilepsy. 4. Use of Cannabis including medical use. 5. Has chronic migraine (more than 15 headache days per month). 6. Changed usage or dosage of migraine preventive medications in the last two months 7. Has undergone nerve block (occipital or other) in the head or neck within the last 2 weeks. 8. Is participating in any other clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>